Portfolio concentration
As of January 31, 2026 · N-PORT
Holdings
33
Top-10 weight
47.03%
Effective holdings
?
The number of equal-weight positions that would produce this portfolio's concentration (1 ÷ Herfindahl index). A 500-stock fund dominated by a few mega-caps might have only ~100 effective holdings.
27
Crowding
?
The value-weighted average number of funds that also own this fund's positions. High = consensus/crowded picks; low = holdings few other funds own.
633.2
Holdings
As of January 31, 2026 · N-PORT| # | Security | Ticker | Shares | Value | % of fund |
|---|---|---|---|---|---|
| 1 | Invesco Private Prime Fund | — | 26,781,082 | $26.78M | 10.18% |
| 2 | ILLUMINA INC | — | 103,203 | $14.94M | 5.68% |
| 3 | GILEAD SCIENCES INC | — | 103,770 | $14.73M | 5.60% |
| 4 | AMGEN INC | — | 38,885 | $13.29M | 5.06% |
| 5 | BIOGEN INC | — | 73,517 | $13.22M | 5.03% |
| 6 | UNITED THERAPEUTICS CORP DEL | — | 27,241 | $12.79M | 4.86% |
| 7 | REGENERON PHARMACEUTICALS INC | — | 17,072 | $12.66M | 4.81% |
| 8 | INCYTE CORP | — | 122,358 | $12.24M | 4.66% |
| 9 | Invesco Private Government Fund | — | 10,305,622 | $10.31M | 3.92% |
| 10 | AMICUS THERAPEUTICS INC | — | 716,939 | $10.25M | 3.90% |
| 11 | ALNYLAM PHARMACEUTICALS INC | — | 29,936 | $10.12M | 3.85% |
| 12 | DYNAVAX TECHNOLOGIES CORP | — | 619,803 | $9.60M | 3.65% |
| 13 | QIAGEN NV ORD SHARES | QIA GR | 150,201 | $8.06M | 3.07% |
| 14 | MANNKIND CORP | — | 1,382,171 | $7.99M | 3.04% |
| 15 | IONIS PHARMACEUTICALS INC | — | 90,302 | $7.47M | 2.84% |
| 16 | ACADIA PHARMACEUTICALS INC | — | 296,675 | $7.46M | 2.84% |
| 17 | ROYALTY PHARMA-A | — | 178,379 | $7.43M | 2.83% |
| 18 | CATALYST PHARMACEUTICALS INC | — | 301,597 | $7.33M | 2.79% |
| 19 | BIOMARIN PHARMACEUTICAL INC | — | 127,758 | $7.22M | 2.75% |
| 20 | BIO-TECHNE CORP | — | 111,680 | $7.16M | 2.72% |
| 21 | COLLEGIUM PHARMACEUTICAL INC | — | 155,580 | $7.14M | 2.72% |
| 22 | EXELIXIS INC | — | 167,824 | $6.94M | 2.64% |
| 23 | HALOZYME THERAPEUTICS INC | — | 95,817 | $6.87M | 2.61% |
| 24 | BIOCRYST PHARMACEUTICALS INC | — | 1,038,146 | $6.83M | 2.60% |
| 25 | NEUROCRINE BIOSCIENCES INC | — | 50,198 | $6.83M | 2.60% |
| 26 | PTC THERAPEUTICS INC | — | 88,821 | $6.71M | 2.55% |
| 27 | PROTAGONIST THERAPEUTICS INC | — | 80,859 | $6.61M | 2.52% |
| 28 | VERICEL CORP | — | 182,370 | $6.56M | 2.50% |
| 29 | TG THERAPEUTICS INC | — | 221,373 | $6.52M | 2.48% |
| 30 | REPLIGEN CORP | — | 42,392 | $6.33M | 2.41% |
| 31 | MADRIGAL PHARMACEUTICALS INC | — | 12,061 | $5.90M | 2.24% |
| 32 | VERACYTE INC | — | 151,832 | $5.78M | 2.20% |
| 33 | Invesco Government & Agency Portfolio, Institutional Class | — | 188,757 | $188.76K | 0.07% |
Machine-readable: JSON · Markdown. Programmatic access via the agent surface.